

Resource Summary Report

Generated by ASWG on Aug 14, 2026

Recombinant Anti-Nucleolin (phospho T84) antibody [EPR8080]

RRID:AB_3075493

Type: Antibody

Proper Citation

Abcam Cat# ab155977, RRID:AB_3075493

Antibody Information

URL: http://antibodyregistry.org/AB_3075493

Proper Citation: Abcam Cat# ab155977, RRID:AB_3075493

Target Antigen: Nucleolin (phospho T84)

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P

Antibody Name: Recombinant Anti-Nucleolin (phospho T84) antibody [EPR8080]

Description: This recombinant monoclonal targets Nucleolin (phospho T84)

Target Organism: human

Clone ID: EPR8080

Antibody ID: AB_3075493

Vendor: Abcam

Catalog Number: ab155977

Record Creation Time: 20250820T002910+0000

Record Last Update: 20250820T082349+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Nucleolin (phospho T84) antibody [EPR8080].

No alerts have been found for Recombinant Anti-Nucleolin (phospho T84) antibody [EPR8080].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Sine CC, et al. (2025) p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Science signaling, 18(914), eadv0415.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer discovery, 14(3), 446.